LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Pacira BioSciences, Inc. Announces Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025 CI
RBC Cuts Price Target on Pacira BioSciences to $42 From $45, Keeps Outperform Rating MT
Barclays Downgrades Pacira BioSciences to Equalweight From Overweight, Adjusts Price Target to $25 From $38 MT
Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic DJ
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell Small Cap Comp Value Index CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 2500 Value Index CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 3000 Value Index CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 2000 Value Index CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 2000 Value-Defensive Index CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) added to Russell 3000E Value Index CI
Transcript : Pacira BioSciences, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 10:30 AM
Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering MT
Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating MT
Transcript : Pacira BioSciences, Inc., Q1 2024 Earnings Call, May 07, 2024
Pacira BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q1 Revenue $167.1M, vs. Street Est of $165.7M MT
Pacira BioSciences, Inc. announces an Equity Buyback for $150 million worth of its shares. CI
Pacira Biosciences, Inc. Reiterates Earnings Guidance for the Full Year 2024 CI
Pacira BioSciences, Inc. authorizes a Buyback Plan. CI
Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM
Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation MT
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis DJ
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy Designation for the Treatment of Osteoarthritis of the Knee CI
Pacira Biosciences Insider Sold Shares Worth $3,656,226, According to a Recent SEC Filing MT
RBC Cuts Price Target on Pacira BioSciences to $45 From $53, Keeps Outperform Rating MT
Chart Pacira BioSciences, Inc.
More charts
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
21.76 USD
Average target price
41.78 USD
Spread / Average Target
+91.99%
Consensus
  1. Stock Market
  2. Equities
  3. PCRX Stock
  4. News Pacira BioSciences, Inc.
  5. Pacira Biosciences Insider Sold Shares Worth $3,656,226, According to a Recent SEC Filing